RecruitingPhase 2NCT07441642
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Studying Medullary sponge kidney
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- FWY003(drug)
- Enrollment
- 272 target
- Eligibility
- 50 years · All sexes
- Timeline
- 2026 – 2029
Study locations (16)
- Salehi Retina Institute, Huntington Beach, California, United States
- Retinal Consultants Medical Group Inc, Sacramento, California, United States
- Advanced Research LLC, Boynton Beach, Florida, United States
- Advanced Research LLC, Deerfield Beach, Florida, United States
- Retina Vitreous Associates of Florida, St. Petersburg, Florida, United States
- Opthamalic Consultants of Boston, Boston, Massachusetts, United States
- NJ Retina, Toms River, New Jersey, United States
- Erie Retina Research LLC, Erie, Pennsylvania, United States
- Retina Consultants TX Rsrch Ctr, Bellaire, Texas, United States
- Retina Consultants of Houston PA, Houston, Texas, United States
- Retina Consultants of Texas, Katy, Texas, United States
- Novartis Investigative Site, Albury, New South Wales, Australia
- Novartis Investigative Site, Parramatta, New South Wales, Australia
- Novartis Investigative Site, Strathfield, New South Wales, Australia
- Novartis Investigative Site, East Melbourne, Victoria, Australia
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07441642 on ClinicalTrials.govOther trials for Medullary sponge kidney
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07489131Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaAlvotech Swiss AG
- ENROLLING BY INVITATIONPHASE2NCT07395986A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07400965Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisGlaukos Corporation
- RECRUITINGPHASE3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc.
- RECRUITINGPHASE2NCT07128628A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseBausch & Lomb Incorporated
- RECRUITINGPHASE3NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc
- RECRUITINGPHASE3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics
- RECRUITINGPHASE3NCT06996080A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLEKodiak Sciences Inc